BiotechTube

SHR-1210+GEMOX

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Cancer

Conditions

Biliary Tract Cancer, Cholangiocarcinoma

Trial Timeline

Feb 10, 2018 → Nov 30, 2020

NCT ID
NCT03486678

About SHR-1210+GEMOX

SHR-1210+GEMOX is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Biliary Tract Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03486678. Target conditions include Biliary Tract Cancer, Cholangiocarcinoma.

What happened to similar drugs?

2 of 20 similar drugs in Biliary Tract Cancer were approved

Approved (2) Terminated (0) Active (18)
✅Tranexamic acid + Standard of CarePfizerApproved
✅abataceptBristol Myers SquibbApproved
🔄Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
🔄durvalumabAstraZenecaPhase 3
🔄Rilvegostomig + Placebo + Capecitabine + Gemcitabine/Cisplatin + S-1 [Tegafur/Oteracil/gimeracil]AstraZenecaPhase 3
🔄Gemcitabine + Cisplatin + Durvalumab + Trastuzumab deruxtecan + RilvegostomigAstraZenecaPhase 3
🔄Durvalumab + Gemcitabine monotherapy + Gemcitabine + cisplatin + Gemcitabine + oxaliplatin + Gemcitabine + carboplatin + Gemcitabine + cisplatin + S-1 + Gemcitabine + S-1 + Gemcitabine + cisplatin + albumin-bound paclitaxelAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03486678Phase 2Completed

Competing Products

20 competing products in Biliary Tract Cancer

See all competitors
ProductCompanyStageHype Score
mFOLFOX regimen + MitazalimabAlligator Bioscience ABPhase 2/3
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
28
Recaticimab and Adebrelimab + GP chemotherapySun PharmaceuticalPhase 2
42
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
E6011 + PlaceboEisaiPhase 2
27
LenvatinibEisaiPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
gemcitabine + cisplatinEli LillyPhase 2
35
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
39
Baricitinib + PlaceboEli LillyPhase 2
27
AbemaciclibEli LillyPhase 2
27
SHR-A1811Jiangsu Hengrui MedicinePhase 2
42
SHR1258Jiangsu Hengrui MedicinePhase 2
27
ApatinibJiangsu Hengrui MedicinePhase 2
31
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
47
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
33
durvalumabAstraZenecaPhase 3
40
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabineAstraZenecaPhase 2/3
38